Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OGA | O60502 | 4/20 | 0.67 |
| ▸ | MEN1 | O00255 | 3/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.51 |
| ▸ | USP2 | O75604 | 2/20 | 0.51 |
| ▸ | HTR1A | P08908 | 1/20 | 0.51 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.51 |
| ▸ | DRD2 | P14416 | 1/20 | 0.51 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.51 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.51 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.51 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.51 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.51 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.51 |
| ▸ | DRD3 | P35462 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19300267 | 0.92 | OGA (0.66) | OGAMEN1KMT2ACYP1A2CYP3A4 | |
| SCHEMBL19300081 | 0.87 | MEN1 (0.58) | OGAMEN1KMT2ACYP1A2CYP3A4 | |
| SCHEMBL19300265 | 0.83 | OGA (0.66) | OGAMEN1KMT2ACYP1A2CYP3A4 | |
| SCHEMBL24812833 | 0.82 | OGA (0.48) | OGAKCNH2ALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL11520142 | 0.82 | MEN1 (0.61) | MEN1KMT2ACYP1A2CYP3A4CYP2D6 | |
| SCHEMBL19461077 | 0.80 | OGA (1.00) | OGA | |
| SCHEMBL17551175 | 0.80 | OGA (1.00) | OGA | |
| SCHEMBL19481321 | 0.79 | MEN1 (0.61) | OGAMEN1KMT2ACYP1A2CYP3A4 | |
| SCHEMBL23653068 | 0.79 | ALDH1A1 (0.54) | OGAMEN1KMT2ACYP1A2CYP3A4 | |
| SCHEMBL12298740 | 0.76 | GLS (0.55) | OGAMEN1KMT2ACYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11591327-B2 | Acid addition salts of piperazine derivatives | ASCENEURON SA (CH) | 2023-02-28 | — | — | US | disclosed |
| EP-3186243-B1 | GLYCOSIDASE INHIBITORS | ASCENEURON SA (CH) | 2021-07-21 | — | — | EP | disclosed |
| US-11046712-B2 | Glycosidase inhibitors | ASCENEURON SA (CH) | 2021-06-29 | — | — | US | disclosed |
| EP-3419976-B1 | ACID ADDITION SALTS OF PIPERAZINE DERIVATIVES | ASCENEURON SA (CH) | 2021-04-07 | — | — | EP | disclosed |
| US-20200385375-A1 | ACID ADDITION SALTS OF PIPERAZINE DERIVATIVES | ASCENEURON SA (CH) | 2020-12-10 | — | — | US | disclosed |
| US-10696668-B2 | Acid addition salts of piperazine derivatives | ASCENEURON SA (CH) | 2020-06-30 | — | — | US | disclosed |
| US-10336775-B2 | Glycosidase inhibitors | ASCENEURON SA (CH) | 2019-07-02 | — | — | US | disclosed |
| US-20190055233-A1 | ACID ADDITION SALTS OF PIPERAZINE DERIVATIVES | ASCENEURON SA (CH) | 2019-02-21 | — | — | US | disclosed |
| US-20170298082-A1 | GLYCOSIDASE INHIBITORS | ASCENEURON SA (CH) | 2017-10-19 | — | — | US | disclosed |
| WO-2017144637-A1 | ACID ADDITION SALTS OF PIPERAZINE DERIVATIVES | ASCENEURON S. A. (CH) | 2017-08-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190055233-A1 | ACID ADDITION SALTS OF PIPERAZINE DERIVATIVES | DNPEP, GAA, SLC30A5 | OGA 452/4885MEN1 4622/4885KMT2A 1757/4885 |
| US-20200385375-A1 | ACID ADDITION SALTS OF PIPERAZINE DERIVATIVES | DNPEP, GAA, SLC30A5 | OGA 452/4885MEN1 4622/4885KMT2A 1757/4885 |
| US-11591327-B2 | Acid addition salts of piperazine derivatives | DNPEP, GAA, SLC30A5 | OGA 452/4885MEN1 4622/4885KMT2A 1757/4885 |
| US-20170298082-A1 | GLYCOSIDASE INHIBITORS | GAA, ENGASE, GBA3 | OGA 77/4885MEN1 3805/4885KMT2A 1511/4885 |
| US-10336775-B2 | Glycosidase inhibitors | GAA, ENGASE, GBA3 | OGA 77/4885MEN1 3805/4885KMT2A 1511/4885 |
| US-11046712-B2 | Glycosidase inhibitors | GAA, ENGASE, GBA3 | OGA 77/4885MEN1 3805/4885KMT2A 1511/4885 |
| US-10696668-B2 | Acid addition salts of piperazine derivatives | DNPEP, GAA, SLC30A5 | OGA 452/4885MEN1 4622/4885KMT2A 1757/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.